Prognostic Factors of Local-Regional Recurrence in Patients with Operable Breast Cancer in Asia: A Meta-Analysis
Prognostic factors for local regional recurrence in operable breast cancer patients in Asia
DOI:
https://doi.org/10.3889/oamjms.2019.151Keywords:
Prognostic factors, Recurrence, Operable breast cancer, Asian PopulationAbstract
BACKGROUND: Cause of recurrence of breast cancer is multifactorial. Also, the occurrence of breast cancer in Asian patients has some different factors from the recurrence of breast cancer in western countries.
AIM: This study aims to determine the prognostic factors of local-regional recurrence in patients with operable breast cancer in Asia.
METHODS: The authors conducted a meta-analysis of published research articles published in an online database of PubMed, ProQuest and EBSCO between January 2000 and July 2018. Pooled risk ratios (RR) were calculated using fixed and random-effect models. Data were processed by using Review Manager 5.3 (RevMan 5.3).
RESULTS: This study reviewed 879 articles. There were 11 studies conducted a systematic review then continued by meta-analysis of relevant data with total patients involved were 5,213 patients. The prognostic factors found of local-regional recurrence in patients with operable breast cancer were Nodal (N) stage with the highest risk ratio (RR = 6.35 [95% CI 3.78-10.67]) followed by HER2 positive (RR = 2.14 [95% CI 1.16-3.97]), stage of cancer (RR = 1.82 [95% CI 1.44-2.31]), tumor size (RR = 1.55 [95% CI 1.04-2.31]), tumor grade (RR = 1.43 [95% CI 1.23-1.65]), PR status (RR = 0.65 [95% CI 0.48-0.88]) and the least was ER status (RR = 0.60 [95% CI 0.39-0.91]). Homogeneity of variance was found in N stage, tumor size and tumor grade for recurrence of operable breast cancer.
CONCLUSION: This meta-analysis confirmed the correlation of N stage, HER2, stage of cancer, tumour size, tumour grade, ER and PR status with recurrence in patients with operable breast cancer in Asia.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Nindrea RD, Aryandono T, Lazuardi L. Breast cancer risk from modifiable and non-modifiable risk factors among women in Southeast Asia: a meta-analysis. Asian Pac J Cancer Prev. 2017; 18:3201–6. PMid:29281867 PMCid:PMC5980871
Nindrea RD, Harahap WA, Aryandono T, Lazuardi L. Association of BRCA1 Promoter methylation with breast cancer in Asia: a meta- analysis. Asian Pac J Cancer Prev. 2018; 19:885–9. PMid:29693332
Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, et al. Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst. 2013; 105:1504–11. https://doi.org/10.1093/jnci/djt244 PMid:24029245
Nishimura R, Osako T, Nishiyama Y, Tashima R, Nakano M, Fujisue M, et al. Evaluation of factors related to late recurrence—later than 10 years after the initial treatment—in primary breast cancer. Oncology. 2013; 85:100–10. https://doi.org/10.1159/000353099 PMid:23867253
Early Breast Cancer Trialists Collaborative Group, Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378:771–84. https://doi.org/10.1016/S0140-6736(11)60993-8
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013; 381:805–16. https://doi.org/10.1016/S0140-6736(12)61963-1
Ditsatham C, Somwangprasert A, Watcharachan K, Wongmaneerung P, Khorana J. Factors affecting local recurrence and distant metastases of invasive breast cancer after breast-conserving surgery in chiang Mai University hospital. Breast Cancer (Dove Med Press). 2016; 18:47-52. https://doi.org/10.2147/BCTT.S99184
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339: b2700. https://doi.org/10.1136/bmj.b2700
Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; 2009.
Elkum N, Dermime S, Ajarim D, Al-Zahrani A, Alsayed A, Tulbah A, et al. Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: the Saudi Arabia experience. BMC Cancer. 2007; 5:222. https://doi.org/10.1186/1471-2407-7-222 PMid:18053234
Son BH, Ahn SH, Kwak BS, Kim JK, Kim HJ, Hong SJ, et al. The recurrence rate, risk factors and recurrence patterns after surgery in 3700 patients with operable breast cancer. J Breast Cancer. 2007; 9:134-144. https://doi.org/10.4048/jbc.2006.9.2.134
Tanioka M, Shimizu C, Yonemori K, Yoshimura K, Tamura K, Kuono T, et al. Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy. Br J Cancer. 2010; 103:297-302. https://doi.org/10.1038/sj.bjc.6605769
Chen ZJ, Yan MY, Zhuang HQ, Hao JL, Li RY, Yuan ZY, et al. Prognostic and Predictive Factors of Early Breast Cancer. Clin Oncol Cancer Res. 2010; 7:246-52. https://doi.org/10.1007/s11805-010-0526-8
Akbari ME, Mozaffar M, Heidari A, Zirakzadeh H, Akbari A, Akbari M, et al. Recurrence and Survival Effect in Breast Conserving Surgery: What are the Predictive and/or Prognostic Factors? Iran J Cancer Prev. 2011; 4:49-53.
Song WJ, Kim KII, Park SH, Kwon MS, Lee TH, Park HK, et al. The Risk Factors Influencing between the Early and Late Recurrence in Systemic Recurrent Breast Cancer. J Breast Cancer. 2012; 15:218–23. https://doi.org/10.4048/jbc.2012.15.2.218 PMid:22807940
Ahn SG, Lee HM, Cho SH, Bae SJ, Lee SA, Hwang SH, et al. The Difference in Prognostic Factors between Early Recurrence and Late Recurrence in Estrogen ReceptorPositive Breast Cancer: Nodal Stage Differently Impacts Early and Late Recurrence. PloS One. 2013; 8:e63510. https://doi.org/10.1371/journal.pone.0063510 PMid:23717438 PMCid:PMC3661516
Wei XQ, Li X, Xin XJ, Tong ZS, Zhang S. Clinical Features and Survival Analysis of Very Young (Age<35) Breast Cancer Patients. Asian Pac J Cancer Prev. 2013; 14:5949-52. https://doi.org/10.7314/APJCP.2013.14.10.5949 PMid:24289606
Wangchinda P, Ithimakin S. Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. World J Surg Oncol. 2016; 14:223. https://doi.org/10.1186/s12957-016-0988-0 PMid:27557635
Ahmadi SA, Arabi M, Payandeh M, Sadeghi M. The recurrence frequency of breast cancer and its prognostic factors in Iranian patients. Int J Appl Basic Med Res. 2017; 7:40-43. https://doi.org/10.4103/2229-516X.198521 PMid:28251106
de Bock GH, Bonnema J, van der Hage J, Kievit J, van de Velde CJ. Effectiveness of routine visits and routine tests in detecting isolated locoregional reccurences afer treatment for early stage invsive breast cancer: meta-analysis and systematic review. J Clin Oncol. 2004; 22:4010-8. https://doi.org/10.1200/JCO.2004.06.080 PMid:15459225
Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996; 14:2738-46. https://doi.org/10.1200/JCO.1996.14.10.2738 PMid:8874335
Thürlimann B. Reducing the risk of early recurrence in hormone-responsive breast cancer. Annals of oncology. 2007; 18(Suppl 8):viii8-17.
Cheng SHC, Tsai SY, Yu BL, Horng CF, Chen CM, Jian JJ, et al. Validating a Prognostic Scoring System for Postmastectomy Locoregional Recurrence in Breast Cancer. Int J Radiat Oncol Biol Phys. 2013; 85:953-8. https://doi.org/10.1016/j.ijrobp.2012.08.042 PMid:23122982
Carter CL, Allen C, Henson DE. Relation of tumor sixe lymph node status and survival in 24,730 breast cancer cases. Cancer. 1989; 63:181-7. https://doi.org/10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90:1371-88. https://doi.org/10.1093/jnci/90.18.1371 PMid:9747868
Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol. 1988; 6:1076-87. https://doi.org/10.1200/JCO.1988.6.7.1076 PMid:2856862
Noguchi S, Koyama H, Kasugai T, Tsukuma H, Tsuji N, Tsuda H, et al. A case-control study on risk factors for local recurrences of distant metastases in breast cancer patients treated with breast-conserving surgery. Oncology. 1997; 54:468-74. https://doi.org/10.1159/000227605 PMid:9394843
Cheng Q, Chang JT, Gwin WR, Zhu J, Ambs S, Geradts J, et al. A signature of epithelial mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype. Breast Cancer Res. 2014; 16:407. https://doi.org/10.1186/s13058-014-0407-9 PMid:25060555 PMCid:PMC4187325
Nindrea RD, Aryandono T, Lazuardi L, Dwiprahasto I. Diagnostic accuracy of different machine learning algorithms for breast cancer risk calculation: a meta-analysis. Asian Pac J Cancer Prev. 2018; 19:1747-52. PMid:30049182 PMCid:PMC6165638
Harahap WA, Sudji IR, Nindrea RD. BRCA1 promoter methylation and clinicopathological characteristics in sporadic breast cancer patients in Indonesia. Asian Pac J Cancer Prev. 2018; 19:2643-49. PMid:30256562
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Wirsma Arif Harahap, Ricvan Dana Nindrea
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0